It has been shown that persistent activation of the NF-κB pathway decreases sensitivity to anti-EGFR monoclonal antibodies and the continued activation of the pathway results in an inflammatory tumor microenvironment, which reduces the effectiveness of anti-EGFR monoclonal antibody treatment. This evidence concerns the gene NFKB1 and neoplasm.